Abstract A28: DCIS disease-free survival in the population-based Wisconsin In Situ Cohort

2011 ◽  
Author(s):  
Brian Sprague ◽  
Vicki McLaughlin ◽  
John Hampton ◽  
Polly Newcomb ◽  
Amy Trentham-Dietz
Keyword(s):  
Disease Free Survival ◽  
Population Based ◽  
Free Survival ◽  
Disease Free

Transoral Laser Surgery for Early Glottic Carcinoma: A Single Surgeon Experience of 101 Consecutive Cases

ORL ◽  
2020 ◽  
pp. 1-6
Author(s):  
Kerem Ozturk ◽  
Goksel Turhal
Keyword(s):  
Overall Survival ◽  
Carcinoma In Situ ◽  
Early Stage ◽  
Case Series ◽  
Disease Free Survival ◽  
Glottic Carcinoma ◽  
Free Survival ◽  
Surgeon Experience ◽  
Disease Free

<b><i>Purpose:</i></b> Investigate the clinical and oncological results of early-stage glottic laryngeal carcinoma patients performed by a single surgeon. <b><i>Methods:</i></b> This study was carried out at a tertiary academic center. A total of 101 patients were included (92 males [91.1%], 9 females [8.9%]). Mean age was 62.98 ± 10.2 years (range 33–87). Recurrence, disease-free survival, overall survival, laryngeal preservation rates were analyzed. <b><i>Results:</i></b> Tumor stage was Tis (carcinoma in situ) in 11 patients (10.9%), T1a in 66 patients (65.3%), T1b in 12 patients (11.9%), and T2 in 12 patients (11.9%). Postoperative pathology was squamous cell carcinoma in 69 patients (68.3%), carcinoma in situ in 26 patients (25.7%), and high-grade dysplasia in 6 patients (5.9%). Five patients (5.0%) underwent type 1, 7 (6.9%) type 2, 45 (44.6%) type 3, 24 (23.8%) type 4, 6 (5.9%) type 5a, 8 (7.9%) type 5c, 4 (4.0%) type 5d, and 2 (2.0%) type 6 cordectomy. Median follow-up time was 30 months (range 14–66). There were 5 recurrences (5.0%). Three-year disease-free survival was 94.4%. Three-year disease-free survival for stage I and II patients was 94.9 and 91.7%, respectively. Overall survival was 93.8%. Only 1 patient died related to cardiovascular disease. Disease-specific survival was 100%. <b><i>Conclusions:</i></b> In conclusion, this is a large case series with good oncological outcomes presented with the perspective of a single surgeon. The data of the study is in accordance with the previous reports.

Influence of place of treatment on diagnosis, treatment, and survival in three pediatric solid tumors.

1984 ◽  
Vol 2 (8) ◽  
pp. 917-923 ◽  
Author(s):  
S Kramer ◽  
A T Meadows ◽  
G Pastore ◽  
P Jarrett ◽  
D Bruce
Keyword(s):  
Solid Tumors ◽  
Wilms Tumor ◽  
Disease Free Survival ◽  
Population Based ◽  
Free Survival ◽  
Pediatric Tumor ◽  
Pediatric Solid Tumors ◽  
Management Procedures ◽  
Disease Free

This study examines differences between cancer centers (CC) and noncancer centers (NCC) in terms of management procedures and outcomes for three pediatric solid tumors: Wilms' tumor (N = 147), rhabdomyosarcoma (N = 87), and medulloblastoma (N = 76). Data were derived for the period 1970-1979 from the population-based Greater Delaware Valley Pediatric Tumor Registry maintained at the Children's Cancer Research Center, which routinely collects data on all childhood neoplasms that occur in a 31-county region. Management measures reviewed included the degree to which important pretreatment evaluations were performed, types of therapy used, and extent of follow-up examinations conducted. Outcome variables were three-year disease-free survival and frequency of deaths related to complications of therapy. Differences in three-year disease-free survival between CC and NCC were noted for medulloblastoma (52% v 24%) and rhabdomyosarcoma (48% v 10%), but not for Wilms' tumor (79% v 68%). Among medulloblastoma patients, differences were detected in the frequency of pretreatment evaluations and in the therapy used. The principal management contrast found in rhabdomyosarcoma was that multiagent chemotherapy was used less often in NCC. Wilms' tumor patients were evaluated and treated similarly in the community versus the CC, except for some contrasts in the surgical approach and the frequency of follow-up for the detection of late complications.

Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study

2015 ◽  
Vol 16 (2) ◽  
pp. 161-168 ◽  
Author(s):  
Claus Anders Bertelsen ◽  
Anders Ulrich Neuenschwander ◽  
Jens Erik Jansen ◽  
Michael Wilhelmsen ◽  
Anders Kirkegaard-Klitbo ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Disease Free Survival ◽  
Complete Mesocolic Excision ◽  
Population Based ◽  
Cancer Surgery ◽  
Population Based Study ◽  
Free Survival ◽  
Mesocolic Excision ◽  
Colon Cancer Surgery ◽  
Disease Free

scholarly journals Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study

2013 ◽  
Vol 141 (1) ◽  
pp. 145-154 ◽  
Author(s):  
Brian L. Sprague ◽  
Vicki McLaughlin ◽  
John M. Hampton ◽  
Polly A. Newcomb ◽  
Amy Trentham-Dietz
Keyword(s):  
Cohort Study ◽  
Disease Free Survival ◽  
Population Based ◽  
Free Survival ◽  
Disease Free

Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years

2018 ◽  
Vol 18 (5) ◽  
pp. e1111-e1116 ◽  
Author(s):  
Giuliano M. Duarte ◽  
Natalie Rios Almeida ◽  
Fernando Tocchet ◽  
Juliana Espinola ◽  
Carolina Teixeira de Resende Barreto ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Carcinoma In Situ ◽  
Disease Free Survival ◽  
Free Survival ◽  
Breast Carcinoma In Situ ◽  
Disease Free

Clinicopathologic Parameters and Survival Data in Non-Metastatic Breast Cancer Patients in Correlation with Tumour Infiltrating Lymphocytes, Androgen Receptor and Insulin-Like Growth Factor Receptor 1 Expression

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 26-26
Author(s):  
JM Njenga ◽  
A El-Gowily ◽  
WO Arafat ◽  
D Abdalla ◽  
YA Rostom
Keyword(s):  
Breast Cancer ◽  
Carcinoma In Situ ◽  
Prognostic Value ◽  
Tumour Size ◽  
Disease Free Survival ◽  
Free Survival ◽  
Clinicopathologic Parameters ◽  
Infiltrating Lymphocytes ◽  
Disease Free

Introduction: The constantly evolving nature of breast cancer (BC) makes it paramount to identify and evaluate more biomarkers that may have a predictive and prognostic value. We explored the relationship between the androgen receptor (AR), insulin-like growth factor 1 receptor (IGF-1R) and tumour infiltrating lymphocytes (TILs), and clinicopathologic variables and survival in BC. Materials and Methods: In this retrospective study, we collected clinical and pathological data of 105 BC patients who had been treated at Alexandria Main University Hospitals from January 2010 to December 2016. These patients’ formalin fixed paraffin-embedded blocks were retrieved and analyzed for AR and IGF-1R expression immunohistochemically; TILs were assessed by hematoxylin and eosin staining. Chi square and Kaplan Meier curves were used to study the correlation between the three biomarkers and clinicopathologic parameters and survival respectively. Results: 59% and 51.4% of patients were AR and IGF-1R positive respectively. AR immunoreactivity correlated with a tumour size less than 5 centimeters (p=0.001), presence of carcinoma in situ (p=0.008), negative Her 2 status (p=0.007) and negative lymphovascular invasion (p<0.001). Negative AR expression predicted a longer disease free survival (p=0.017). A positive IGF-1R was associated with carcinoma in situ (p<0.001) and negative extra-nodal extension (p=0.042) but no impact on the disease free survival (p=0.227). A high TIL expression was associated with a tumour size less than 5 centimeters (p=0.005), invasive lobular carcinoma (p=0.006), carcinoma in situ (p=0.047), negative LVI (p<0.001) and longer survival. A positive AR expression was associated with a positive IGF-1R expression (p<0.001). Conclusions: AR, IGF-1R and TILs correlate differently with various clinicopathologic variables used in BC; in addition they all have a prognostic value. The two receptors are a promising target in BC. More clinical studies are required to further confirm the utility of these three biomarkers.

Sign in / Sign up

Export Citation Format

Share Document